alliqua holdings inc company profile  bloomberg feedback alliqua holdings inc public company company profile sector unclassifiable industry unclassifiable subindustry unknown corporate information address  stony hill road suite  yardley pa  united states phone  fax  from the web sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data alliqua biomedical home about company about alliqua our mission careers people management team board of directors medical advisory board news  events press releases alliqua in the news conference schedule products all products biovance® interfyl™ mist therapy® therabond® d silverseal® hydress® resources custom hydrogels customer support scientific research investors investor relations news events  webcasts company information investor presentations financial information stock information sec filings corporate governance careers contact restoring tissue rebuilding lives alliqua biomedical nasdaq alqa is a regenerative technology company building a suite of regenerative solutions for both wound and tissue repair allowing clinicians to utilize the latest technological advances to bring improved patient outcomes in a cost efficient manner biovance®    interfyl™    mist therapy®    therabond® d    silverseal®    hydress® news and developments alliqua biomedical inc announces partnership with partners capital group to provide ultramist® customers with new equipment financing programs june  alliqua biomedical inc reports first quarter of fiscal year  financial results may  alliqua biomedical inc receives extension from nasdaq to regain compliance with minimum bid price requirement april  alliqua biomedical inc announces preliminary first quarter fiscal  revenue and updates fiscal year  outlook earnings conference call scheduled for may   april  alliqua biomedical inc to present new data at the spring  symposium on advanced wound care april  alliqua biomedical inc announces closing of approximately  million public offering april  alliqua biomedical inc announces pricing of public offering of common stock march   view all news and developments  company  about us our mission  careers people  management team  board of directors  medical advisors featured products  biovance®  mist therapy® therabond® d resources  custom hydrogels  customer support  scientific research news  events  press releases  alliqua in the news  conference schedule investors  investor overview presentations  stock information product portfolio alliqua biomedical is building a suite of technological solutions that allow clinicians to utilize the latest advances in regenerative therapies to bring improved patient outcomes to their practices our portfolio includes the mist® therapy system a noncontact lowfrequency ultrasound biovance® human amniotic membrane allograft and interfyl™ human connective tissue matrix in flowable and particulate form that support restoration of form and function through tissue regeneration facilitating improved patient outcomes view products find a local sales representative enter your us zip code to find an alliqua sales representative in your area get alliqua news and developments by email about alliqua alliqua biomedical nasdaq alqa is a functional regeneration company building a suite of technological solutions that allow clinicians to utilize the latest advances in regenerative therapies to bring improved patient outcomes to their practices recent newsalliqua biomedical inc announces partnership with partners capital group to provide ultramist® customers with new equipment financing programs june  alliqua biomedical inc reports first quarter of fiscal year  financial results may   quick linksabout alliqua products customer support conference schedule investor overview contact us contact us alliqua biomedical inc  stony hill road suite  yardley pa    wndcare    general productinfoalliquacom investors iralliquacom   alliquacom  disclaimer and terms of use  sales portal products follow us tweets by alliquainc product portfolio  alliqua biomedical home about company about alliqua our mission careers people management team board of directors medical advisory board news  events press releases alliqua in the news conference schedule products all products biovance® interfyl™ mist therapy® therabond® d silverseal® hydress® resources custom hydrogels customer support scientific research investors investor relations news events  webcasts company information investor presentations financial information stock information sec filings corporate governance careers contact product portfolio all sort products all antimicrobial protection human biologic hydration ultrasound healing therapy biovance® interfyl™ ultramist® ultrasound healing therapy therabond® d silverseal® hydress® about alliqua alliqua biomedical nasdaq alqa is a functional regeneration company building a suite of technological solutions that allow clinicians to utilize the latest advances in regenerative therapies to bring improved patient outcomes to their practices recent newsalliqua biomedical inc announces partnership with partners capital group to provide ultramist® customers with new equipment financing programs june  alliqua biomedical inc reports first quarter of fiscal year  financial results may   quick linksabout alliqua products customer support conference schedule investor overview contact us contact us alliqua biomedical inc  stony hill road suite  yardley pa    wndcare    general productinfoalliquacom investors iralliquacom   alliquacom  disclaimer and terms of use  sales portal products follow us tweets by alliquainc dnasdaq cm stock quote  alliqua holdings inc  bloomberg markets error could not add to watchlist x  watchlist alliqua holdings inc dus nasdaq cm pending listing dus is pending listing usd volume  before its here its on the bloomberg terminal learn more volume  current pe ratio ttm  earnings per share  ttm  market cap usd  shares outstanding  pricesales ttm  dividend indicated gross yield  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later there are currently no press releases for this ticker please check back later q alliqua biomedical inc  marketwatch latest news dow    nasdaq    sp      pm et updated does your child have a question there’s a smart toy for that  pm et updated house votes to prevent disgruntled customers from being able to sue their bank  pm et updated one depressing reason millions of people are locked out of the american dream  pm et updated what everyone can learn from jared kushner’s ad hoc approach to meetings  pm et one version of gop healthcare bills fails in senate vote  pm et updated george clooney and angelina jolie’s directorial projects could be the most soughtafter tickets at tiff  pm et john mccain gives trump a win then gives senate an earful  pm et updated paypal earnings partnerships help but are benefits already priced in  pm et updated amd puts intel in the crosshairs with fastandcheap threadripper chip  pm et amd earnings give investors what they wanted now it must deliver  pm et house passes bill hitting russia with new sanctions  pm et wsj interview trump doesnt rule out firing sessions  pm et former trump campaign chief manafort strikes deal to avoid public testimony  pm et updated this quant pro and card counter says gambling can make you a better investor  pm et updated bitcoin digital currencies retreat from records  pm et this is what it will take for bitcoin to become a legit currency  pm et updated emerging markets fund manager favors bangladesh and kenya and avoids korea and taiwan  pm et uss thunderbolt fires warning shots at iranian vessel in gulf  pm et updated here’s one trump fan who might make you some money  pm et chegg shares sink after secondquarter loss log in home edgar online  edg  q k get email alerts q alliqua biomedical inc by published nov    pm et share edgar online via comtex  item  managements discussion and analysis of financial condition and results of operations the following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and related notes above forwardlooking statements this quarterly report on form q contains forwardlooking statements which include information relating to future events future financial performance strategies expectations competitive environment and regulation words such as may should could would predict potential continue expect anticipate future intend plan believe estimate and similar expressions as well as statements in future tense identify forwardlooking statements forwardlooking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will actually be achieved forwardlooking statements are based on information we have when those statements are made or our managements good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forwardlooking statements important factors that could cause such differences include but are not limited to  inadequate capital  the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives  our ability to obtain reimbursement from third party payers for our products  our ability to achieve and maintain minimum sales requirements under our license agreements  our ability to obtain and maintain regulatory approval of our existing products and any future products we may develop  our ability to cure or obtain forbearance or waivers for existing covenant defaults under our outstanding indebtedness and to remain in compliance with our debt covenants  market acceptance of our existing and future products  loss or retirement of key executives  our plans to make significant additional outlays of working capital before we expect to generate significant revenues and the uncertainty regarding when we will begin to generate significant revenues if we are able to do so  an unfavorable decision on product reimbursement  adverse economic conditions andor intense competition  loss of a key customer or supplier  entry of new competitors and products  adverse federal state and local government regulation  technological obsolescence of our products  technical problems with our research and products  risks of mergers and acquisitions including the time and cost of implementing transactions and the potential failure to achieve expected gains revenue growth or expense savings  price increases for supplies and components and  the inability to carry out research development and commercialization plans for a discussion of these and other risks that relate to our business and investing in shares of our common stock you should carefully review the risks and uncertainties described under the heading part i  item a risk factors and elsewhere in this quarterly report on form q and in our annual report on form k for the year ended december   the forwardlooking statements contained in this quarterly report on form q are expressly qualified in their entirety by this cautionary statement we do not undertake any obligation to publicly update any forwardlooking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events overview we are a regenerative technologies company that commercializes differentiated regenerative medical products which assist the body in the repair of human tissue our commercial wound care portfolio currently consists of three product categories wound bed preparation and stimulation human biologics and antimicrobial protection we currently market mistr ultrasound healing therapy which uses painless noncontact lowfrequency ultrasound to stimulate cells below the wound bed to promote the healing process biovancer and interfyltm human connective tissue matrix which are human biologic regenerative technologies and therabond dr which is advanced dressing incorporating its proprietary therabond dr antimicrobial barrier systems technology we seek to broaden this product portfolio by identifying acquiring and integrating technologies and products that enhance our product portfolio while diversifying our customer base and growing our sales footprint recent events senior secured term loan facility as of september   we were in default of a covenant pertaining to trailing twelvemonth revenue under our credit agreement as a result of our failure to achieve  of gross revenue for the twelvemonth period ended september   as of september   we had an outstanding principal amount of approximately  million under this credit agreement under an agreement dated november   the lender agreed to forbear from exercising any rights and remedies related to the default until november   but has reserved the rights commencing november   to pursue any rights and remedies available to it including but not limited to declaring all or any portion of the outstanding principal amount to be immediately due and payable imposing a default rate of interest as specified in the credit agreement or pursing the lenders rights and remedies as a secured party under the ucc as a secured lender in addition the lender has a lien on substantially all of our assets and as a result of the default may seek to foreclose on some or substantially all of our assets after the expiration of the forbearance we are in negotiations with other financing parties to refinance this debt however no assurance can be given that we will be able to obtain additional debt to refinance our existing obligations on commercially reasonable terms or at all acquisition consistent with our strategy of expanding our product portfolio of regenerative technologies on october   we entered into a contribution agreement and plan of merger the contribution and merger agreement with alliqua holdings inc our wholly owned subsidiary new alliqua chesapeake merger corp a wholly owned subsidiary of new alliqua merger sub and soluble systems llc soluble pursuant to which among other things we will reorganize into a new holding company by merging merger sub with and into us with us surviving as a wholly owned subsidiary of new alliqua in addition following the effective time of the merger soluble will contribute substantially all of its assets to new alliqua and new alliqua will assume or payoff certain liabilities of soluble in exchange for certain consideration in the merger i each outstanding share of our common stock par value  per share will automatically be converted into one share of new alliquas common stock par value  per share ii each of our outstanding options restricted shares and restricted or phantom stock units will continue to vest or accelerate and will automatically be converted from a right to acquire our common stock to a right to acquire new alliqua common stock on the same terms and iii each outstanding warrant will be converted into a right to acquire new alliqua common stock on the same terms subject to the terms and conditions of the contribution and merger agreement as part of the consideration for the asset contribution soluble will receive i newly issued shares of new alliqua common stock representing approximately  of the total number of shares of issued and outstanding new alliqua common stock after giving effect to the new issuance and based on the number of shares of our common stock outstanding as of october   ii warrants to purchase an aggregate of  shares of new alliqua common stock at an exercise price of  per share and iii credit for a portion of the payments made at closing by us to solubles senior lender and a third party supplier which has been allocated to us and will not be considered an adjustment to the shares issuable as part of the equity consideration the exact number of shares of new alliqua common stock issuable to soluble as part of the equity consideration will be determined at the closing of the transactions based on the value of certain indebtedness of soluble that will be paid off or assumed by new alliqua at closing and subject to certain other adjustments and escrow holdbacks set forth in the contribution and merger agreement in addition the estimated ownership percentage above with respect to the shares of new alliqua common stock to be issued to soluble does not take into account i the issuance of additional shares of new alliqua common stock upon any subsequent exercise of the warrants issued to soluble and ii the issuance of any additional shares of our common stock or securities convertible into or exercisable for our common stock in connection with the financing contemplated by the contribution and merger agreement the closing of the transactions contemplated by the contribution and merger agreement is conditioned upon among other things us securing debt or equity financing or combination thereof that results in gross proceeds of at least  million inclusive of any current indebtedness of soluble or us that is assumed restructured or refinanced by the combined company we currently expect to restructure the existing senior debt obligations for both us and soluble totaling approximately  million the balance of the proceeds would be used for costs related to the acquisition as well as to meet our working capital requirements the transactions are expected to close during the first quarter of  subject to the receipt of any required approvals and the satisfaction or waiver of the closing conditions contained in the contribution and merger agreement however it is possible that factors outside the control of the parties could require the parties to complete the transactions at a later time or not complete it at all soluble is the manufacturer andor distributor of a line of advanced wound care products under the brand names theraskinr and theragauzer solubles lead product theraskinr is a cryopreserved human skin allograft for nonresponsive chronic wounds solubles patented smrt polymer technology is found in its advanced wound care dressing theragauzer which regulates moisture differentially across a wound bed to aid in wound healing without maceration asset sale in order to add capital and to focus on future investments on commercializing our own regenerative technologies effective june   we entered into a purchase agreement the purchase agreement with bsn medical inc bsn whereby we agreed to sell to bsn i all of the our rights including all distribution rights exclusivity rights intellectual property rights and marketing rights collectively the rights to the sorbion product line pursuant to its distribution agreement as amended the sorbion agreement with sorbion gmbh  co kg and ii the unsold inventory of sorbion products that we previously purchased in existence as of the closing which occurred upon execution and delivery of the purchase agreement in consideration for the sale of the rights and the unsold sorbion inventory to bsn bsn agreed to pay i  million related to the purchase of the rights and the termination of the sorbion agreement and certain other agreements between the parties and ii up to  related to the unsold sorbion inventory upon our completion of the obligations to deliver all remaining and qualifying unsold sorbion inventory with such payment amount varying based upon the condition of the sorbion inventory as specified in the purchase agreement the results of operations for the three and nine months ending september   and  reflect our continuing operations results of operations three months ended september   compared to the three months ended september   revenues net for the three months ended september   revenues increased by approximately  or  to  million from  million for the three months ended september   the increase in our overall revenue was primarily due to an increase in product sales the components of revenue were as follows for the three months ended september   and  in thousands three months ended september    revenues product     contract manufacturing   total revenues net     our growth rates for the three months ended september   and  were as follows in thousands three months ended september    revenue growth      growth over prior year     comprised of  of organic growth      of acquisition growth          organic revenue growth represents growth from contract manufacturing and sales of our hydrogel therabond mist biovance and interfyl products  organic growth represents growth from all lines of business excluding mist which is included acquisition growth described below  acquisition revenue growth represents growth from the sale of the mist therapy product line acquired in the purchase of celleration gross profit our gross profit was  million or  of sales for the three months ended september   compared to gross profit of  million or  of sales for the three months ended september   gross margin on our product sales was approximately  for the three months ended september   compared to  for the three months ended september   the decline in our gross margin was primarily due to lower margins on mist therapy system sales we expect our product gross margin to approximate  in future quarters dependent upon product mix we also expect our overall gross profit to increase as a result of product sales becoming a higher proportion of our total sales the components of cost of revenues are as follows for the three months ended september   and  in thousands three months ended september    cost of revenues materials and finished products     stockbased compensation   compensation and benefits   depreciation and amortization   equipment production and other expenses   total cost of revenues     selling general and administrative expenses the following table highlights selling general and administrative expenses by type for the three months ended september   and  in thousands three months ended september    selling general and administrative expenses compensation and benefits     stockbased compensation   professional fees   marketing   depreciation and amortization   royalty fees   other expenses   total selling general and administrative expenses     selling general and administrative expenses decreased by  million to  million for the three months ended september   as compared to  million for the three months ended september   compensation and benefits expense was approximately  million for the three months ended september   and  stockbased compensation decreased by  to  million for the three months ended september   as compared to  million for the three months ended september   the decrease in stockbased compensation is primarily due to the decrease in awards granted and the lower weighted average estimated fair value of options granted during the three months ended september   as compared to the three months ended september   the increase in other selling general and administrative expense including professional fees is primarily in support of our revenue growth other selling general and administrative expenses consist of costs associated with our selling efforts and general management including recruiting information technology travel training and third party logistics research and product development expenses during the three months ended september   and  we incurred research and product development expenses of  and  respectively related to a randomized controlled trial for our biovance product in chronic diabetic foot wounds we have experienced slower than expected patient enrollment and projected costs to complete the trial are significantly higher than we previously expected in addition we believe there is no longer a business need for this trial due to the amount of patient data currently available our success in getting government and commercial insurance coverage for biovance and our recent increase in biovance sales due to these factors we have decided to terminate patient enrollment for the biovance trial we expect our research and product development costs related to this trial to continue through the completion of study closedown during the first quarter of  milestone expense to licensor during the three months ended september   we incurred  of milestone expense for achieving two of the three milestones under the license agreement with hli related to the launch of the interfyl product we initiated sales and marketing efforts of interfyl in september  and will pay hli  related to the first commercial sale of interfyl in the flowable matrix configuration and  related to the first commercial sale of interfyl in the particulate form commercial sales of both configurations occurred in september  we believe interfyl will be a significant product offering in our portfolio of regenerative technologies as it can be used in a broad range of surgical applications acquisitionrelated expenses during the three months ended september   we incurred  in acquisitionrelated costs related to the planned acquisition of soluble during the three months ended september   we incurred  related to the acquisition of celleration acquisition related costs include professional fees associated with due diligence and other activities related to acquisition we expect to incur acquisitionrelated costs through the first quarter of  when we anticipate closing the acquisition of soluble change in fair value of contingent consideration liability during the three months ended september   we recorded an increase in the fair value of the contingent consideration liability of approximately  compared to an increase of  in the three months ended september   the increase recorded during the three months ended september   is related to the accretion of the fair value of this liability other income during the three months ended september   we recorded other income of  we were required to perform certain services related to the transition of the sorbion business to bsn as compensation bsn paid us  for the services completed during the three months ended september   this compensation was recognized over the day service period and is included in other income for the three months ended september   nine months ended september   compared to the nine months ended september   revenues net for the nine months ended september   revenues increased by  million or  to  million from  million for the nine months ended september   the increase in our overall revenue was primarily due to increase in product sales the components of revenue were as follows for the nine months ended september   and  in thousands nine months ended september    revenues product     contract manufacturing   total revenues net     our growth rates for the nine months ended september   and  were as follows in thousands nine months ended september    revenue growth      growth over prior year     comprised of  of organic growth      of acquisition growth          organic revenue growth represents growth from contract manufacturing and sales of our hydrogel therabond biovance and interfyl products and mist subsequent to may    organic growth represents growth from all lines of business excluding mist which is included acquisition growth described below  acquisition revenue growth represents growth from the sale of the mist therapy product line acquired in the purchase of celleration through may   acquisition growth represents growth from the sale of mist gross profit our gross profit was  million or  of sales for the nine months ended september   compared to gross profit of  million or  of sales for the nine months ended september   gross margin on our product sales was approximately  for the nine months ended september   compared to  for the nine months ended september   we expect our product gross margin to approximate  in future periods dependent upon product mix we also expect our overall gross profit to increase as a result of product sales becoming a higher proportion of our total sales the components of cost of revenues are as follows for the nine months ended september   and  in thousands nine months ended september    cost of revenues materials and finished products     stockbased compensation   compensation and benefits   depreciation and amortization   equipment production and other expenses   total cost of revenues     selling general and administrative expenses the following table highlights selling general and administrative expenses by type for the nine months ended september   and  in thousands nine months ended september    selling general and administrative expenses compensation and benefits     stockbased compensation   professional fees   marketing   depreciation and amortization   royalty fees   other expenses   total selling general and administrative expenses     selling general and administrative expenses increased by  million to  million for the nine months ended september   as compared to  million for the nine months ended september   compensation and benefits increased by  million to  million for the nine months ended september   as compared to  million for the nine months ended september   the increase in compensation and benefits was primarily due to the increase in the number of fulltime employees during the nine months ended september   compared to september   as a result of the acquisition of celleration in may  as well as increase in commissions related to the increase in revenue stockbased compensation decreased by  million to  million for the nine months ended september   as compared to  million for the nine months ended september   the decrease in stockbased compensation is primarily due to the lower weighted average estimated fair value of options granted during the nine months ended september   as compared to the nine months ended september   the increase in other selling general and administrative expense including professional fees is primarily in support of our revenue growth and as a result of our acquisition of celleration other selling general and administrative expenses consist of costs associated with our selling efforts and general management including recruiting information technology travel training and third party logistics research and product development expenses during the nine months ended september   and  we incurred research and product development expenses of  and  respectively related to a randomized controlled trial for our biovance product in chronic diabetic foot wounds we have experienced slower than expected patient enrollment and projected costs to complete the trial are significantly higher than we previously expected in addition we believe there is no longer a business need for this trial due to the amount of patient data currently available our success in    nov   c  cybernet data systems inc all rights reserved more from marketwatch most popular the biggest dog in the dow might soon break free here’s why amazon facebook and the gang are not going to take down this market amd earnings how did we get here sp  nasdaq finish at records as investors cheer earnings russell gordys ranch collection across the american west marketwatch partner center we want to hear from you join the conversation comment sponsored headlines advanced search stocks columns authors topics no results found marketwatchcom topics bulletin investor alert tokyo markets close in currencies europe markets london markets topics istanbul brexit guns millennials immigration apple congatopicsmainhtml  subjects in the news credit currency markets supermarkets textiles gas prices airlines oil currencies us stocks retail federal reserve us dollar united kingdom europe european markets energy stocks copper people in the news trump donald buffett warren hill david rather dan brin sergey king david lewis michael perry rick berlusconi silvio mccain john musk elon carter jimmy obama barack clinton bill jackson michael bloomberg michael putin vladimir snow john companies in the news miners connor american international group lilly eli  co dow chemical dupont apple inc american manufacturing ford motor general motors jones m co bank of america corp caterpillar inc dow jones  co google inc mcdonalds corp news corp organizations in the news european union consumers union general assembly small business administration european central bank nasdaq stock market world bank world trade organization bank of england federal reserve bank of new york investment company institute new york stock exchange college board new york university state university of new york university of massachusetts university of washington washington state university browse topics a b c d e f g h i j k l m n o p q r s t u v w x y z  log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pdoes your child have a question there’s a smart toy for that phouse votes to prevent disgruntled customers from being able to sue their bank pone depressing reason millions of people are locked out of the american dream pwhat everyone can learn from jared kushner’s ad hoc approach to meetings pone version of gop healthcare bills fails in senate vote pgeorge clooney and angelina jolie’s directorial projects could be the most soughtafter tickets at tiff pjohn mccain gives trump a win then gives senate an earful ppaypal earnings partnerships help but are benefits already priced in pamd puts intel in the crosshairs with fastandcheap threadripper chip pamd earnings give investors what they wanted now it must deliver phouse passes bill hitting russia with new sanctions pwsj interview trump doesnt rule out firing sessions pformer trump campaign chief manafort strikes deal to avoid public testimony pthis quant pro and card counter says gambling can make you a better investor pbitcoin digital currencies retreat from records pthis is what it will take for bitcoin to become a legit currency pemerging markets fund manager favors bangladesh and kenya and avoids korea and taiwan puss thunderbolt fires warning shots at iranian vessel in gulf phere’s one trump fan who might make you some money pchegg shares sink after secondquarter loss loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  alliqua holdings inc home search signinup contracts dictionary clauses companies people about faq blog home sample contracts by company alliqua holdings inc alliqua holdings inc loading address  stony hill road suite  yardley pa  phone  sample contracts alliqua holdings inc – noncompetition agreement december nd  whereas alliqua biomedical inc alliqua alliqua holdings inc a delaware corporation and a whollyowned subsidiary of alliqua parent and together with alliqua the alliqua entities chesapeake merger corp a delaware corporation and a whollyowned subsidiary of parent and soluble systems llc a virginia limited liability company the company have entered into that certain contribution agreement and plan of merger dated as of october   the contribution and merger agreement alliqua holdings inc – form of lockup agreement november th  reference is made to that certain contribution agreement and plan of merger dated as of october   the contribution and merger agreement by and among alliqua biomedical inc a delaware corporation alliqua alliqua holdings inc a delaware corporation and a whollyowned subsidiary of alliqua parent chesapeake merger corp a delaware corporation and a whollyowned subsidiary of parent merger sub and together with alliqua and parent the alliqua entities and soluble systems llc a virginia limited liability company the company pursuant to which the company shall receive shares of parent common stock and warrants as consideration for the contributed assets at the closing for the purposes hereof any terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the contribution and merger agreement in consideration of the company and the alliqua entities entering into the transactions and for other good and valuabl alliqua holdings inc – form of voting agreement november th  this voting agreement dated as of   this agreement is by and between alliqua biomedical inc formerly alliqua holdings inc a delaware corporation alliqua and soluble systems llc a virginia limited liability company soluble alliqua and soluble are individually referred to herein as a party and collectively as the parties alliqua holdings inc – form of warrant agreement to purchase shares of the common stock of alliqua holdings inc dated as of   the effective date november th  whereas alliqua biomedical inc a delaware corporation alliqua alliqua holdings inc a delaware corporation and a whollyowned subsidiary of alliqua parent chesapeake merger corp a delaware corporation and a whollyowned subsidiary of parent and soluble systems llc a virginia limited liability company the warrantholder have entered into that certain contribution agreement and plan of merger dated as of october   the contribution and merger agreement and × have an account sign in here law insider recover your password no account register now no account register now sign in by using one of this services or forgot your password have an account sign in here join law insider for free by using one of this services or by registering you agree to our terms of service contract and agreement category list home search signinup contracts dictionary clauses companies people about faq blog sample contract categories a b c d e f g h i j k l m n o p q r s t u v w x y z abcdefghijklmnopqrstuvwxyz k delaware k new york k california k texas k agreement k nevada k florida k maryland k illinois k employment agreement k washington k amended and restated k massachusetts k new jersey k pennsylvania k georgia k colorado k ohio k minnesota k virginia k north carolina k incentive plan k credit agreement k amendment k connecticut k michigan k indiana k registration rights agreement k recitals k tennessee k arizona k missouri k purchase agreement k promissory note k indenture k warrant k louisiana k kansas k utah k wisconsin k oklahoma k securities purchase agreement k agreement and plan of merger k iowa k supplemental indenture k note k equity incentive plan k kentucky k stock purchase agreement k alabama × have an account sign in here law insider recover your password no account register now no account register now sign in by using one of this services or forgot your password have an account sign in here join law insider for free by using one of this services or by registering you agree to our terms of service quote  alliqua biomedical inc alqa home about company about alliqua our mission careers people management team board of directors medical advisory board news  events press releases alliqua in the news conference schedule products all products biovance® interfyl™ mist therapy® therabond® d silverseal® hydress® resources custom hydrogels customer support scientific research investors investor overview newsevents  webcastscompany informationfinancial informationstock informationsec filingscorporate governance careers contact quote loading data overview news events  webcasts company information financial information stock information quote charts historical data analyst coverage sec filings corporate governance email alerts tear sheet ir contacts rss news feed get alliqua news and developments by email subscribe about alliqua alliqua biomedical inc nasdaq alqa is a provider of advanced wound care solutions our products are intended to enhance the wound care practitioner’s ability to deal with the challenges of healing both chronic and acute wounds recent news alliqua biomedical inc announces partnership with partners capital group to provide ultramist® customers with new equipment financing programs alliqua biomedical inc reports first quarter of fiscal year  financial results alliqua biomedical inc receives extension from nasdaq to regain compliance with minimum bid price requirement investor relations investor overview newsevents  webcastscompany informationfinancial informationstock informationsec filingscorporate governance contact us alliqua biomedical inc  stony hill road suite yardley pa    wndcare    general productinfoalliquacom investors iralliquacom   alliquacom  disclaimer and terms of use  sales reps products follow us tweets by alliquainc press releases  alliqua biomedical inc alqa home about company about alliqua our mission careers people management team board of directors medical advisory board news  events press releases alliqua in the news conference schedule products all products biovance® interfyl™ mist therapy® therabond® d silverseal® hydress® resources custom hydrogels customer support scientific research investors investor overview newsevents  webcastscompany informationfinancial informationstock informationsec filingscorporate governance careers contact press releases alliqua biomedical inc to acquire celleration inc expands proprietary product portfolio and salesforce in the advanced wound care market langhorne pa feb   globe newswire  alliqua biomedical inc nasdaqalqa alliqua or the company a provider of advanced wound care products today announced that it has signed a definitive agreement to acquire celleration inc celleration for an initial purchase price of approximately  million which is comprised of both cash and stock the merger agreement provides for additional contingent payments in stock and cash under certain circumstances if stated revenue thresholds are reached over the next two years ending december   or if certain milestones are satisfied in connection with product sales in the uk related links pdf release pdf celleration is a privately held medical device company based in eden prairie minnesota which is focused on developing and commercializing the mist therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds cellerations mist therapy system is an fda k cleared device that uses painless noncontact lowfrequency ultrasound to stimulate cells below the wound bed in order to promote the healing process celleration generated total revenue of approximately  million during its fiscal year ended december   since cellerations mist therapy system was commercialized in  mist therapy has been performed more than  million times on over  patients in the us and the uk cellerations mist therapy system is supported by extensive clinical study data which has been produced in the past several years showing that mist therapy positively impacts critical aspects of the wound healing process most recently in a prospective randomized controlled trial conducted in  us outpatient healthcare facilities and published in the january  edition of ostomy  wound management mist therapy demonstrated a statistically significant improvement in the healing rate over the standard of care treatment for venous leg ulcers it is with this body of clinical data that the mist therapy was given a new reimbursement payment for outpatient services that became effective january   and we believe now more effectively reflects both the clinical efficacy and the economic benefits of the technology cellerations innovative mist therapy technology is positioned perfectly within alliquas business model said david johnson chief executive officer of alliqua mist therapy is a differentiated wound care treatment which is supported by a breadth of data that demonstrates its clinical efficacy and strong economic value proposition cellerations therapeutic devices mist and ultramist™ are fda k cleared receive favorable reimbursement and carry a highmargin profile likewise cellerations focus on developing novel approaches for the treatment of wounds aligns exceptionally well with our vision of building a suite of advanced wound care solutions continued david johnson in addition to the differentiated product offering we were attracted to cellerations leadership role in advancing the science and practice of wound healing in working with medical professionals and providers which we believe has helped the company earn the favorable reimbursement decision in recent months further this transaction will nearly double our sales force and we look forward to incremental improvements in sales force productivity as we begin marketing the combined companys suite of proprietary products finally we are very pleased to welcome mark wagner cellerations president and ceo who will be joining our board of directors upon the closing of the transaction this transaction presents an exciting opportunity for the two companies and their employees who will be able to market a broader portfolio of treatments to a combined customer base and a common call point commented mark wagner cellerations president and ceo with an impressive product portfolio and sales infrastructure the combined company will be wellpositioned to capitalize on the large and rapidly growing market for advanced wound care treatments both companies believe strongly in evidence based medicine and delivering products that accelerate healing and minimize retreatment rates which most importantly benefits patients payers and providers cowen and company llc served as the alliquas exclusive financial advisor in connection with this transaction financing alliqua has entered into a commitment letter for a senior secured term loan with perceptive advisors in the principal amount of  million in order to finance the initial cash purchase price further details of the acquisition and commitment letter can be found in alliquas form k that will be filed with the sec terms and approvals the transaction is expected to close in the second quarter of  and is subject to customary closing conditions including alliqua shareholder approval conference call alliqua will host a conference call for analysts and investors tomorrow tuesday february   beginning at  am et to discuss the celleration transaction individuals interested in listening to the conference call may dial  for domestic callers or  for international callers and provide access code  a replay of the call will be available for  days and can be accessed by dialing  for domestic callers or  for international callers the conference call will also be available via a webcast on the investors relations section of the companys web site at httpiralliquacom about alliqua biomedical incalliqua is a provider of advanced wound care solutions through its sales and distribution network together with its proprietary products alliqua provides a suite of technological solutions to enhance the wound care practitioners ability to deal with the challenges of healing both chronic and acute wounds alliqua currently markets its line of hydrogel products for wound care under the silverseal® and hydress® brands as well as the sorbion sachet s® and sorbion sana® wound care products and its therabond® d advanced dressing which incorporates the therabond® d antimicrobial barrier systems technology it also markets the advanced wound care product biovance® as part of its licensing agreement with celgene cellular therapeutics in addition alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry utilizing its proprietary hydrogel technology alliquas electron beam production process located at its  square foot gmp manufacturing facility in langhorne pa allows alliqua to develop and custom manufacture a wide variety of hydrogels alliquas hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries for additional information please visit httpwwwalliquacom to receive future press releases via email please visit httpirstockprcomalliquaemailalerts about celleration inccelleration inc is a privately held medical device company celleration develops and markets a proprietary technology that has been proven to accelerate healing in wounds by delivering therapeutic low frequency ultrasound without direct contact of the delivery device to the wound surface cellerations core product the mist therapy system has been clinically shown to positively impact all critical aspects of the wound healing process providing clinical and economic benefits to institutions treating nonresponding wounds mist therapy has been performed more than  million times on over  patients there are  peer reviewed published articles including five randomized controlled trials and one metaanalysis documenting the clinical outcomes of mist legal notice regarding forwardlooking statementsthis release contains forwardlooking statements forwardlooking statements are generally identifiable by the use of words like may will should could expect anticipate estimate believe intend or project or the negative of these words or other variations on these words or comparable terminology the reader is cautioned not to put undue reliance on these forwardlooking statements as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue including but not limited to the adequacy of the companys liquidity to pursue its complete business objectives inadequate capital the companys ability to obtain reimbursement from third party payers for its products loss or retirement of key executives adverse economic conditions or intense competition loss of a key customer or supplier entry of new competitors and products adverse federal state and local government regulation technological obsolescence of the companys products technical problems with the companys research and products the companys ability to expand its business through strategic acquisitions the companys ability to integrate acquisitions and related businesses price increases for supplies and components and the inability to carry out research development and commercialization plans in addition other factors that could cause actual results to differ materially are discussed in our annual report on form k filed with the sec on march   and our most recent form q filings with the sec investors and security holders are urged to read these documents free of charge on the secs web site at httpwwwsecgov we undertake no obligation to publicly update or revise our forwardlooking statements as a result of new information future events or otherwise httpwwwowmcomarticleprospectiverandomizedcontrolledtrialcomparingeffectsnoncontactlowfrequency contact investor relations westwicke partners on behalf of alliqua biomedical inc mike piccinino cfa  alliquabiomedicalwestwickecom source alliqua inc released february   overview news press releases email alerts events  webcasts company information financial information stock information sec filings corporate governance email alerts tear sheet ir contacts rss news feed get alliqua news and developments by email subscribe about alliqua alliqua biomedical inc nasdaq alqa is a provider of advanced wound care solutions our products are intended to enhance the wound care practitioner’s ability to deal with the challenges of healing both chronic and acute wounds recent news alliqua biomedical inc announces partnership with partners capital group to provide ultramist® customers with new equipment financing programs alliqua biomedical inc reports first quarter of fiscal year  financial results alliqua biomedical inc receives extension from nasdaq to regain compliance with minimum bid price requirement investor relations investor overview newsevents  webcastscompany informationfinancial informationstock informationsec filingscorporate governance contact us alliqua biomedical inc  stony hill road suite yardley pa    wndcare    general productinfoalliquacom investors iralliquacom   alliquacom  disclaimer and terms of use  sales reps products follow us tweets by alliquainc microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft alliqua inc alqa  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in alliqua inc alqa median target price   upside positive ratings  of  analysts latest  cowen  outperform     view all analyst ratings for alqa » alliqua inc alqa  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in alliqua inc alqa median target price   upside positive ratings  of  analysts latest  cowen  outperform     view all analyst ratings for alqa » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising